Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AstraZeneca to Simultaneously Start All PI Trials Worldwide
December 25, 2006
- SMO Group Holds CRC Training Seminar
December 25, 2006
- Sanofi-aventis to Start Large Epidemiological Study in Cerebral Infarction Patients
December 25, 2006
- Pazufloxacin Can Now Be Used as 1st-Choice Drug: Toyama, MPC
December 25, 2006
- Wyeth, Kyushu Univ. Moving Forward with Their R&D Alliance
December 25, 2006
- Chugai to Copromote Otsuka's Antiplatelet Agent Pletaal
December 25, 2006
- REGULATORY NEWS IN BRIEF
December 25, 2006
- Pfizer to Continue Launching Series of New Drugs: President Iwasaki
December 25, 2006
- PMDA to Increase Transparency on Posting of Ex-Employees of Companies
December 25, 2006
- BUSINESS NEWS IN BRIEF
December 25, 2006
- Nippon Keidanren Leaders Exchange Opinions with Korosho Leaders
December 25, 2006
- Novartis Highlights Strong R&D Pipeline
December 25, 2006
- Korosho Hears from 5 Parties to Promptly Bring New Drugs to Patients
December 25, 2006
- R&D NEWS IN BRIEF
December 25, 2006
- System That Fairly Awards Innovation Needed: WG for New Industry Vision
December 25, 2006
- Risk Classification for OTC Drugs Nearly Complete: PFSB
December 25, 2006
- Transfer Price Taxation System to Be Revised in FY2007
December 25, 2006
- Asahi Kasei Medical, Kuraray Medical to Integrate Businesses
December 25, 2006
- Tie-ups of Hansha Spreading to Kanto, Shikoku: Mr Eguchi
December 25, 2006
- MEDICAL DEVICE NEWS IN BRIEF
December 25, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…